Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125
Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125
奥本海默将再生元制药的目标股价从1,125美元调整至1,175美元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册